Bethesda’s Northwest (NWBO) Stock Gains 16% YTD

This year Northwest stock could reach as high as $1.04 while developing its cancer battling DCVax drug and creating new milestones to increase its production and marketing. Here, a few development key stages happened several months ago as they pushed NWBO to cross the $1 mark.

Chemotherapy, Radiation May Not Be Needed to Kill Cancer Cells, Finds Study

  • Three months ago Northwest got $15 million in external funding
  • Approval for manufacturing clinical-grade cell therapy medicines
  • At Sawston, UK facility the company started commencing production of the initial dendritic cell cancer vaccine

On November 29 2021 the company has received a 22-month loan of 15 million US dollars and has no payments for eight months with a 14-month amortization period. The loan has 8% interest and an original issue discount of 10%. The lender has got a win-win deal based on exercising a flexible right by becoming a possibly significant shareholder.

UK Medicines and Healthcare Products Regulatory Agency (MHRA) has given a license to the company for producing clinical-grade therapies and drugs in cancer-fighting developments at its Sawston, UK building.

The Sawston facility took two preparations to get approval from MHRA for manufacturing various (clinical grade) cell therapy products in order to create a smooth business in Europe. In the UK the company is clearly focused on developing ADCV (Autologous Dendritic Cell Vaccine) that is allowing it to anticipate phase 1A.Cancer cells can pick up fatty coatings to spread further in the body | New Scientist